image credit- freepik
Hangzhou Sciwind Biosciences has announced that China's National Medical Products Administration (NMPA) has approved Ecnoglutide injection for chronic weight management in Chinese adults with overweight or obesity.
Ecnoglutide injection is the world's first approved cAMP-biased GLP-1RA for weight management. Through its unique biased mechanism, it achieves highly effective weight reduction in the Chinese population, with an average 15.1% placebo-adjusted weight loss, and 92.8% of patients reaching clinical meaningful weight loss.
This marks a breakthrough in the field of weight management, and provides a precise new pathway for scientific, long‑acting and healthy weight loss.
Based on the globally pioneering cAMP-biased GLP-1 receptor agonism mechanism, Ecnoglutide injection selectively activates the cAMP signaling pathway and minimises β-arrestin recruitment, distinguishing it from conventional non-biased GLP-1RAs. This mechanism delivers potent and sustained weight loss with no obvious plateau phase, and supports concurrent improvement in metabolism and reduced chronic disease risk alongside weight reduction, perfectly aligning with the core goals of healthy weight management.
The prevalence of overweight and obesity in China continues to rise. As an independent chronic disease and a major risk factor for multiple comorbidities, obesity has become a major public health issue and the sixth leading risk factor for death and disability in China.
